Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 May;62(5):435–439. doi: 10.1136/ard.62.5.435

Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment

C Fiehn 1, Y Hajjar 1, K Mueller 1, R Waldherr 1, A Ho 1, K Andrassy 1
PMCID: PMC1754523  PMID: 12695156

Abstract

Objective: To evaluate the differences in the outcome of lupus nephritis diagnosed either in the 1980s or the 1990s in Heidelberg, Germany.

Methods: Fifteen patients with biopsy confirmed lupus nephritis (LN) were followed up between 1980 and 1989 and 41 patients were followed up between 1990 and 2000. Their status at diagnosis and their treatment schedules and outcome were analysed. 68% had WHO IV nephritis.

Results: In the decade from 1990 to 2000 there was significantly less proteinuria (46 v 17 g/l, p=0.008), significantly lower rates of renal failure (40% v 17%, p=0.02), and fewer histological signs of chronicity (33% v 10%, p=0.01) at the time of diagnosis of LN than in the decade from 1980 to 1989. The mean (SD) time from the first appearance of proteinuria until kidney biopsy was significantly shorter in the later decade (15.4 (15.6) v 3.9 (4.7) months). Although treatment schedules were not significantly different, the outcome of the disease was significantly better in the patients who were diagnosed with LN between 1990 and 2000 (p=0.045). Whereas 6/15 (40%) patients between 1980 and 1989 had terminal renal failure after a mean time of 94 months, in the group of 1990–2000 no patient developed terminal renal failure (median observation time 24 months). In both groups one patient died from infection. A high chronicity index in histology and the presence of arterial hypertension or renal failure, or both, at the time of diagnosis were significant risk factors for the development of terminal renal failure in the course of the disease.

Conclusions: The outcome of patients with newly diagnosed LN was significantly better between 1990 and 2000 than between 1980 and 1989. Kidney damage and chronic histological changes at time of diagnosis were significantly less common between 1990 and 2000, which is attributable to earlier diagnosis and treatment in the later decade.

Full Text

The Full Text of this article is available as a PDF (121.7 KB).

Figure 1.

Figure 1

Open in a new tab

Renal survival curve of patients with lupus nephritis diagnosed in the decade 1990–2000 (group II, n=41) in comparison with 1980–1989 (group I, n=15). Whereas six patients of the earlier decade had terminal renal failure in the follow up, no patient of the later decade had the same event, which is significant (p=0.045). In both groups one patient died from infection.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Shakra M., Urowitz M. B., Gladman D. D., Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995 Jul;22(7):1259–1264. [PubMed] [Google Scholar]
  2. Abu-Shakra M., Urowitz M. B., Gladman D. D., Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. 1995 Jul;22(7):1265–1270. [PubMed] [Google Scholar]
  3. Austin H. A., 3rd, Boumpas D. T., Vaughan E. M., Balow J. E. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995;10(9):1620–1628. [PubMed] [Google Scholar]
  4. Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–640. doi: 10.1002/art.1780350606. [DOI] [PubMed] [Google Scholar]
  5. Bono L., Cameron J. S., Hicks J. A. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999 Apr;92(4):211–218. doi: 10.1093/qjmed/92.4.211. [DOI] [PubMed] [Google Scholar]
  6. Boumpas D. T., Austin H. A., 3rd, Vaughn E. M., Klippel J. H., Steinberg A. D., Yarboro C. H., Balow J. E. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 Sep 26;340(8822):741–745. doi: 10.1016/0140-6736(92)92292-n. [DOI] [PubMed] [Google Scholar]
  7. Cameron J. S. Lupus nephritis. J Am Soc Nephrol. 1999 Feb;10(2):413–424. doi: 10.1681/ASN.V102413. [DOI] [PubMed] [Google Scholar]
  8. Cameron J. S. Lupus nephritis. J Am Soc Nephrol. 1999 Feb;10(2):413–424. doi: 10.1681/ASN.V102413. [DOI] [PubMed] [Google Scholar]
  9. Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Aydintug A. O., Jedryka-Góral A., de Ramón E., Fernández-Nebro A. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999 May;78(3):167–175. doi: 10.1097/00005792-199905000-00003. [DOI] [PubMed] [Google Scholar]
  10. Fauci A. S., Haynes B. F., Katz P., Wolff S. M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76–85. doi: 10.7326/0003-4819-98-1-76. [DOI] [PubMed] [Google Scholar]
  11. Gilboe I. M., Kvien T. K., Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol. 2001 Feb;28(2):266–274. [PubMed] [Google Scholar]
  12. Houssiau Frédéric A., Jadoul Michel. Cytotoxic therapy of lupus nephritis: recent developments. Nephrol Dial Transplant. 2002 Jun;17(6):955–957. doi: 10.1093/ndt/17.6.955. [DOI] [PubMed] [Google Scholar]
  13. Houssiau Frédéric A., Vasconcelos Carlos, D'Cruz David, Sebastiani Gian Domenico, Garrido Ed Enrique de Ramon, Danieli Maria Giovanna, Abramovicz Daniel, Blockmans Daniel, Mathieu Alessandro, Direskeneli Haner. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 Aug;46(8):2121–2131. doi: 10.1002/art.10461. [DOI] [PubMed] [Google Scholar]
  14. Lim C. S., Chin H. J., Jung Y. C., Kim Y. S., Ahn C., Han J. S., Kim S., Lee J. S. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol. 1999 Sep;52(3):139–147. [PubMed] [Google Scholar]
  15. Martins L., Rocha G., Rodrigues A., Santos J., Vasconcelos C., Correia J., Farinha F., Almeida I., Barbosa P., Guimarães S. Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol. 2002 Feb;57(2):114–119. doi: 10.5414/cnp57114. [DOI] [PubMed] [Google Scholar]
  16. Moroni G., Quaglini S., Maccario M., Banfi G., Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996 Dec;50(6):2047–2053. doi: 10.1038/ki.1996.528. [DOI] [PubMed] [Google Scholar]
  17. Najafi C. C., Korbet S. M., Lewis E. J., Schwartz M. M., Reichlin M., Evans J., Lupus Nephritis Collaborative Study Group Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001 Jun;59(6):2156–2163. doi: 10.1046/j.1523-1755.2001.00730.x. [DOI] [PubMed] [Google Scholar]
  18. Ruiz-Irastorza G., Khamashta M. A., Castellino G., Hughes G. R. Systemic lupus erythematosus. Lancet. 2001 Mar 31;357(9261):1027–1032. doi: 10.1016/S0140-6736(00)04239-2. [DOI] [PubMed] [Google Scholar]
  19. Rush P. J., Baumal R., Shore A., Balfe J. W., Schreiber M. Correlation of renal histology with outcome in children with lupus nephritis. Kidney Int. 1986 May;29(5):1066–1071. doi: 10.1038/ki.1986.108. [DOI] [PubMed] [Google Scholar]
  20. Schwartz M. M., Lan S. P., Bernstein J., Hill G. S., Holley K., Lewis E. J. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int. 1992 Sep;42(3):743–748. doi: 10.1038/ki.1992.342. [DOI] [PubMed] [Google Scholar]
  21. Schwartz M. M., Lan S. P., Bernstein J., Hill G. S., Holley K., Lewis E. J. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int. 1992 Sep;42(3):743–748. doi: 10.1038/ki.1992.342. [DOI] [PubMed] [Google Scholar]
  22. Swaak A. J., van den Brink H. G., Smeenk R. J., Manger K., Kalden J. R., Tosi S., Domljan Z., Rozman B., Logar D., Pokorny G. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus. 2001;10(1):51–58. doi: 10.1191/096120301666282314. [DOI] [PubMed] [Google Scholar]
  23. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  24. Uramoto K. M., Michet C. J., Jr, Thumboo J., Sunku J., O'Fallon W. M., Gabriel S. E. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999 Jan;42(1):46–50. doi: 10.1002/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  25. Urowitz M. B., Gladman D. D. Evolving spectrum of mortality and morbidity in SLE. Lupus. 1999;8(4):253–255. doi: 10.1191/096120399678847821. [DOI] [PubMed] [Google Scholar]
  26. Ward M. M., Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med. 1992 Oct;152(10):2082–2088. [PubMed] [Google Scholar]
  27. Ward M. M., Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med. 1992 Oct;152(10):2082–2088. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES